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Background: Doxorubicin (DOX), an anthracycline antibiotic is one of the most effective anticancer drug used in
the treatment of variety of cancers .Its use is limited by its cardiotoxicity. The present study was designed to assess
the role of a natural product resveratrol (RSVL) on sensitization of mammary carcinoma (Ehrlich ascites carcinoma)
to the action of DOX and at the same time its protective effect against DOX-induced cardiotoxicity in rats.
Methods: Ehrlich ascites carcinoma bearing mice were used in this study. Percent survival of tumor bearing mice
was used for determination of the Cytotoxic activity of DOX in presence and absence of RSVL. Uptake and cell cycle
effect of DOX in tumor cells in the presence of RSVL was also determined. Histopatholgical examination of heart
tissues after DOX and/or RSVL therapy was also investigated.
Results: DOX at a dose level of 15 mg/kg increased the mean survival time of tumor bearing mice to 21 days
compared with 15 days for non tumor-bearing control mice. Administration of RSVL at a dose level of 10 mg/kg
simultaneously with DOX increased the mean survival time to 30 days with 70% survival of the tumor-bearing
animals. RSVL increased the intracellular level of DOX and there was a strong correlation between the high cellular
level of DOX and its cytotoxic activity. Moreover, RSVL treatment showed 4.8 fold inhibition in proliferation index of
cells treated with DOX. Histopathological analysis of rat heart tissue after a single dose of DOX (20 mg/kg) showed
myocytolysis with congestion of blood vessels, cytoplasmic vacuolization and fragmentation. Concomitant
treatment with RSVL, fragmentation of the muscle fiber revealed normal muscle fiber.
Conclusion: This study suggests that RSVL could increase the cytotoxic activity of DOX and at the same time
protect against its cardiotoxicity.
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Doxorubicin (DOX) was introduced in cancer therapy in
the late 1960s. It has emerged as one of the most potent
broad-spectrum antitumor anthracycline antibiotics. DOX
can be administered as a single agent or in combination
with other chemotherapeutic agents. It is widely used in
the treatment of variety of cancers, including leukemias,
lymphomas, soft-tissue sarcomas, and solid tumors. Its
cytotoxic effects on malignant cells, however, are compli-
cated by an increase in the risk of cardiotoxicity [1,2].* Correspondence: moneimosman@hotmail.com
1Pharmacology Department, Faculty of Medicine, King Abdulaziz University,
Jeddah, Saudi Arabia
2National Cancer Institute, Cairo University, Cairo, Egypt
Full list of author information is available at the end of the article
© 2013 Osman et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orDue to the increasing worldwide prevalence and health
burden of doxorubicin induced cardiotoxicity, it has be-
come increasingly important to find pharmacological rem-
edies to protect against this serious side effect, in an
attempt to minimize DOX effective chemotherapeutic dose
and thereby its side effects, a variety of approaches have
been investigated [3-5]. One of them is the search for nat-
ural compounds with chemopreventive or anticancer pro-
perties that can be used in combination with doxorubicin.
Resveratrol (RSVL) (trans – 3, 5, 4 – trihydroxystilbene) is
a naturaly occurring poly-phenolic compound found pri-
marily in root extracts of the oriental plant Polygonum
cuspidatum and many other plant species [6]. It is highly
abundant in skins of red grapes and moderately abundant
in peanuts and blueberries [6]. It has recently beenLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Effects of RSVL treatment (10 mg/kg,i.p.) on the
therapeutic action of DOX (15 mg/kg,i.p.) in mice bearing





Control 15 ± 4.06 a, b 0/10
RSVL (10 mg/kg) 13 ± 3.55 b 0/10
DOX (15 mg/kg) 21 ± 9.19 a, b 1/10
DOX (15 mg/kg) + RSVL (10 mg/kg)
(supplied simultaneously)
30 ± 5.29 a, b 7/10
Each data represents the mean ± S.D. of ten mice. The mean Survival time is
the time in days until animals die.
aSignificantly different from control at P-value ≤ 0.05. bSignificantly different
from DOX at P-value ≤ 0.05.
Osman et al. Cancer Cell International 2013, 13:52 Page 2 of 8
http://www.cancerci.com/content/13/1/52discovered that it has many beneficial effects in different
biological systems, which include anti-inflammatory, anti-
oxidant, anti-neoplastic, anti-carcinogenic, anti-tumorigenic,
cardioprotective, neuroprotective, anti-aging and antiviral
effects [6]. Its potential chemopreventive and chemothera-
peutic activities have been demonstrated in all three stages
of carcinogenesis (initiation, promotion, and progression)
[7]. A study from our lab used a model of DOX-induced
heart damage in rats, we found that pre-treatment with
aged garlic extract, a strong antioxidant, offered protection
against DOX-induced myocardial cell damage [8]. Recently,
Osman et al. [9] reported sensitization of human breast
cancer cells to the action of DOX in an attempt to
minimize DOX effective dose and thereby its side effects.
Therefore The present study was undertaken to test
whether resveratrol in vivo could potentiate the antitumor
properties of doxorubicin and the mechanisms by which




Doxorubicin hydrochloride and RSVL were purchased
from Sigma–Aldrich Co. (St. Louis, MO, USA). The stock
















RSVL + DOXO (supplied
simultaneously)
Figure 1 Effect of RSVL treatment (10 mg/kg,i.p.) on the cytotoxic act
ascites cells.preserved at -20°C. The solutions were diluted in normal
saline immediately before each experiment to the desired
final concentration.
Animals and tumor
Female Swiss albino mice (8 weeks of age, 20–25 g body
weight) were obtained from King Fahd Medical Research
Center, King Abdulaziz University, Jeddah, Saudi Arabia.
The animals were acclimatized for one week. A commercial
balanced diet and water, ad libitum were provided through-
out the experiment. A line of Ehrlich ascites carcinoma
cells (EAC) cells was supplied by Prof. Abdel-Moneim and
maintained in our laboratory by weekly I.P. transplantation
of 2.5 × 106 cells/mouse. This study was approved by the
ethical committee of King Abdulaziz Hospital.
Evaluation of antitumor activity
The effect of RSVL on the antitumor activity of DOX
was evaluated using the modified regimen of Donenko
et al. [10]. In brief, EAC cells were inoculated I.P. into
forty female Swiss albino mice (2.5 × 106 cells/mouse).
Twenty four hours later, mice were equally divided into
four groups. Group 1: mice were administered normal
saline i.p. (0.2 ml/20 gm) and served as control. Group
II was administered DOX 15 mg/kg i.p. Group III re-
ceived a single dose of RSVL (10 mg/kg,i.p.) and Group
IV received RSVL simultaneously with DOX.
Assessment of doxorubicin cellular accumulation
DOX cellular accumulation assessment in Ehrlich ascites
cells was performed using spectrofluorometer (F-2000
Fluorescence spectrophotometer Hitachi, Japan) according
to the method of Kitagawa et al. [11]. Ehrich ascites cells
were inoculated as described above at 10×106 cells/mouse.
Twenty-four hours later RSVL (15 mg/kg) was injected
i.p. simultaneously with DOX (20 mg/kg). Tumor sam-
ples were obtained at fixed times after DOX treatment,
washed, counted, and DOX fluorescence intensity was10 20 30 40
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Figure 2 Effect of resveratrol treatment on the doxorubicin level in Ehrlich ascites cell. Doxorubicin was injected (20 mg/kg i.p.) in tumor-
bearing mice treated with 10 mg /kg,i.p. RSVL in simultaneous manner (red box) or saline (blue diamond suit). Each data represents the mean ± S.D. of
six mice. aSignificantly different from DOX after 3 hours of treatment at P-value ≤ 0.05. bSignificantly different from DOX after 24 hours of treatment at
P-value ≤ 0.05. cSignificantly different from DOX after 48 hours of treatment at P-value ≤ 0.05.
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ex = 496 nm and λ em = 592 nm, respectively to deter-
mine DOX concentration.
DOX cellular accumulation ratio
¼ DOX concentration in RSVL treaated cells
DOX concentration in cells treated with DOX alone
Cell cycle analysis
Ehrlich ascites cells were inoculated i.p. (10×106 cells/
mouse). Twenty-four hours later, DOX (20 mg/kg,i.p.) was
injected simultaneously with RSVL (10 mg/kg,i.p.). T umor
cells were obtained at fixed times after DOX treatment. Cell
cycle analysis was performed using flow cytometer (Becton
Dicknson, BD, FACSCalbur, USA) according to the method
of Smets et al. [12].Cardio toxic effect of DOX in presence of RSVL
Twenty-five male Wistar rats were divied into five equal
groups consisting of 5 animals each and housed in a
room with regular 12 hr. light/dark cycle with free ac-
cess to food and water. Two groups (I and II) were used
as a control and received normal saline (i.p.) and RSVL
(15 mg/kg,i.p.). Group III received a single dose of DOX
at dose of 20 mg/kg. Groups IV received DOX simultan-
eously with RSVL. Twenty four hours after DOX treat-
ment, animals were anesthetized and heart specimens
were fixed in 10% formalin for light microscopic study
of the heart tissues.Statistical analysis
Statistical analysis was performed using SPSS (statistical
package of social sciences, version 16). One way analysis
of variance (ANOVA) followed by least significant diffe-
rence (LSD) for post hoc analysis, was used for multiple
comparisons. Statistical significance was acceptable to a
level of p < 0.05.Results
Survival of tumor bearing mice
Table 1 and Figure 1 show the effect of treatment with
DOX and/or RSVl on the survival of tumor bearing mice.
Tumor-bearing control mice showed mean survival time
of 15 days, whereas administration of a single dose of
DOX (15 mg/kg,i.p.) increased the mean survival time to
21 days, with 10% long term survivors. Concomitant treat-
ment with RSVL (10 mg/kg,i.p.) increased the mean sur-
vival time of tumor-bearing mice to 30 days with 70% long
term survivors.DOX level in tumor cells
Figure 2 shows the cellular level of DOX in Ehrlich ascites
cells after a single dose of DOX (20 mg/kg,i.p.) and/or
RSVL (10 mg/kg,i.p.). RSVL significantly increased the cel-
lular level of DOX at all the time points tested, the ma-
ximum level appeared 3 hours after treatment. Forty-eight
hours after treatment the levels of DOX decreased but still
higher after combination therapy (1.7 fold more). DOX
cellular accumulation ration were 1.55, 1.85 and 1.67 after
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Figure 4 Effect of DOX and/or RSVL on the proliferation index. aSignificantly different from Control at P-value ≤ 0.05. bSignificantly different
from DOX after 3 h of treatment at P-value ≤ 0.05. cSignificantly different from DOX after 24 h of treatment at P-value ≤ 0.05.
Figure 3 Effect of DOX (15 mg/kg) and/or RSVL (10 mg/kg) on cell cycle phase distribution of Ehrlich ascites cells.
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Figure 5 A photomicrograph of the myocardium of a normal
rat showing branching cardiac muscle fibers (b) with central
oval euchromatic nuclei (thick arrow). The fibroblast in the
endomycium revealed deeply stained flat nuclei (thin
arrows). H&E × 400.
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progression in Ehrlich cells
Treatment with RSVL induced accumulation of cells in
G0/G1 phase after 24 hours, while DOX treatment
showed 17 fold increase in the number of cells in G0/G1
phase with less number of cells in S phase (Figure 3).
Simultaneous treatment of RSVL with DOX resulted in
increased number of cells in G0/G1 phase (about 85%)
with reduced number of cells in S phase compared to
DOX or RSVL.
Three and twenty –four hours after DOX treatment the
proliferation index (S phase + G2/M phase) inhibited by
about 6 and 78%, respectively, whereas concomitant treat-
ment with RSVL reduced the proliferation index signifi-
cantly by about 29 and 85%, respectively (Figure 4).Figure 6 A photomicrograph of the myocardium of a rat given
RSVL (10 mg/kg,i.p.) showing a general architecture almost
similar to group I (control) except for slight congestion of the
blood vessels (arrows). H&E × 400.Protective effect of RSVL against DOX-induced
cardiotoxicity
Light microscopic examination of heart section of albino
rats after a single dose of RSVL (10 mg/kg,i.p.) showed a
general architecture almost similar to control (Figures 5
and 6). However, DOX (20 mg/kg,i.p.) treated animals
showed area of myocytolsis (Figure 7a) with congestion of
blood vessels (Figure 7b), cytoplasmic vacuolization or frag-
mentation (Figure 7c). In addition there was hyalinization
of the muscle fiber (Figure 7d) and chromatin margination
of some nuclei while others were pyknotic (Figure 7e). Con-
comitant administration of RSVL ( 10 mg/kg,i.p) with DOX
showed normal muscle fibers with central oval nuclei and
some pyknotic nuclei, while fragmentation of the muscle
fiber were revealed (Figure 8).
Discussion
Doxorubicin is an excellent antitumor drug for treating
several types of solid tumor, leukemia and lynphomas.
However, acute or chronic toxicity is the dose limiting fac-
tor whereas, acute cardio toxicity represented mainly by
transient symptoms, such as arrhythmias, while chronic
toxicity can develop into irreversible cardiomyopathy,
which affects approximately 30-40% of the patients who
receive 500 mg/mm2 total dose [1]. In the current study
we investigated the modulatory effect of a natural product
RSVL on the cytotoxic activity of DOX against the growth
of Ehrlich ascites carcinoma in mice. At the same time, its
protective effect against DOX-induced cardiotoxicity was
investigated. In this study, RSVL enhanced the cytotoxic
activity of DOX against the growth of Ehrlich ascites car-
cinoma cells. Treatment of tumor bearing mice with
RSVL +DOX showed 7 –fold increase in long-term sur-
vival in comparison to DOX treated mice alone (Table 1
and Figure 1). RSVL is known to has antitumor activity
in vitro [9]. Our study showed high cellular level of DOX
concentrations in Ehlrich cells when RSVL was concomi-
tantly administered with DOX (Figure 2). There was an in-
crease in DOX accumulation ratio for cells treated with
DOX and RSVL. The increase in DOX cellular uptake in-
side Ehrlich cells may be explained based on inhibition of
P-glycoprotein that plays very important role in the ab-
sorption, distribution, and elimination of DOX and thus
determine its efficacy and toxicity [13,14]. Supporting the
previous work, cell cycle analysis showed that RSVL de-
creased the proliferation index (S phase + G2/M phase) of
cells treated with DOX to 29 and 85% compared with 6
and 78% in cells treated with DOX alone, 3 and 24 hours
after DOX treatment, respectively. This agrees with the
uptake study, where DOX uptake was at highest level
3 hours after DOX treatment. Al-Shabanh et al. [15]
reported similar results where the peak of DOX uptake in
tumor was observed three hours after DOX treatment. Re-





Figure 7 A photomicrograph of the myocardium of a rat given DOX ( 20 mg/kg,i.p.) a :showing areas of myocytolysis(m). H&E × 400.
b: showing congestion of blood vessels (arrows). H&E × 400. c: showing myocytes with cytoplasmic vacuolization (V) or fragmentation (F). Some
nuclei were pyknotic (thin arrow) while others revealed chromatin margination (thick arrow). H&E × 400. d: showing hyalinization of the muscle
fiber (thick arrow). Notice the congested blood vessel (thin arrow). H&E × 400. e: showing chromatin margination of some nuclei (black arrows)
while others were pyknotic (white arrows). Areas empty of muscle fibers around the pyknotic nuclei were evident (thick arrow). H&E × 400.
Figure 8 A photomicrograph of the myocardium of a rat given
RSVL (10 mg/kg,i.p.) concomitantly with DOX showing normal
muscle fibers with their central oval nuclei (black arrows). Still
some pyknotic nuclei (dashed arrows) and fragmentation (F) of the
muscle fiber were revealed H&E × 400.
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RSVL. It has been shown that P388 leukemia cells syn-
chronized in S and G2/M phases were more sensitive to
DOX than cells in G1 phase [16], however, our study
showed accumulation of Ehrlich cells in G1 phase by
RSVL,DOX and their combination with significant de-
crease in number of cells in S phase which may be due in-
hibition of the enzyme used for DNA replication [17-19]
or increase expression of positive G1/S regulators, such as
cyclin D1 and cyclin E which are responsible for S phase
entry [20,21]. Although our finding is somehow contra-
dictory to other results reported a significant accumula-
tion of some cancer cells in S-phase after RSVL treatment
[22] This could be due to different cell lines used and the
deregulation of expression and/or activities of different
isoforms of cyclins and CDKs [23].
RSVL which is known to display antitumor activity
[24], has been shown to have potent cardioprotective ef-
fect. This was observed in our study, where DOX
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vacuolization or fragmentation. Some nuclei were pyknotic
while others revealed chromatin margination (Figure 7a,
7b, 7c). In the presence of RSVL cardiac myocytes showed
normal muscle fibers with their central oval nuclei in
addition to some pyknotic nuclei and fragmentation of the
muscle fiber (Figure 8). In animal models of cardiovascular
disease, RSVL has been shown to protect the heart from
ischemi reperfusion injury, reduce blood pressure and car-
diac hypertrophy on hypertensive animals and has been
shown to slow progressionof athrosclerosis [25]. The exact
mechanism of cardioprotective is not understood, but it
could be due to inhibition of DOX-induction of the rapid
increase in ROS accumulation in cardiac cell mitochondria
[26] by increasing superoxide dismutase activity [27],
suggesting that the antioxidant properties of resveratrol
may play a role in its cardioprotective effects. However,
antioxidant therapies have failed to produce satisfactory re-
sults in clinical trials [28], casting doubt on the notion that
the inhibition of oxidative stress is the only mechanism re-
sponsible for the cardioprotective effects of resveratrol
which may need further investigations. In conclusion, this
study suggests that RSVL treatment increased the cytotoxic
activity of DOX against the growth of Mammary tumor
in vivo and could be as a promising cardioprotective agent
against DOX-induced cardiotoxicity.
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